

Figure S1. GFP-AD-MSC enhance tumour growth with an acid-independent mechanism. (a) Left panel: representative image of luciferase assay in a subcutaneously injected OS xenograft after 15 days; right panel: tumour growth in group #1 and #2 of the animal trial n. 2 (see Table 2), as measured by the Total flux ($n = 6$, $*p < 0.05$, Mann Whitney U test, median and percentiles are shown); (b) n. of Ki67 positive cells that were also negative for GFP, in luc-143b spheroids, enriched or not with GFP-AD-MSC, and cultured in medium at different pH ($n = 6$, $***p < 0.001$, Mann Whitney U test, mean \pm SEM); (c) Left panel: representative images of luciferase assay in a intratibially injected OS xenografts after 15 days; right panel: tumour growth in the tibia in the group #3 and #4 of the animal trial n. 6 (see Table 2) at 8 days, as measured by the Total flux ($n = 6$, $*p < 0.05$, Mann Whitney U test, median and percentiles are shown).





Figure S2: Original Images of Western Blot analysis of Fig. 1G.

Table S1. List of primers.

Definition	Locus	Reference GeneBank	Forward	Reverse	Aplicon Length
Human 18S ribosomal	X03205	X03205.1 X03205	5'-gcaattattcccatgaacg-3'	5'-gggacttaatcaacgcaagc-3'	68 nt
Homo sapiens glyceraldehyde-3- phosphate dehydrogenase (GAPDH)	NM_002046	NM_002046.3	5'-agccacatcgctcagacac-3'	5'-gcccaatacgaccaaattcc-3'	66 nt
Homo sapiens tyrosine 3- monooxygenase/tryptop han 5-monooxygenase activation protein zeta (YWHAZ), transcript variant 1	NM_003406	NM_003406.3	5'-ccgttacttgctgaggttg-3'	5'-tgcttggtgactgatgac-3'	67 nt
Human beta- glucuronidase (GUSB)	HUMGLCB	M15182.1 M15182	5'-cgcctgcctatctgtattc-3'	5'-tccccacaggagtgtag-3'	91 nt
Homo sapiens ATPase H ⁺ transporting V1 subunit B2 (ATP6V1B2)	NM_001693	NM_001693.3	5'-tggccgaagacttcttg-3'	5'-ccgaaatgccagtctgaatc-3'	90 nt
Homo sapiens interleukin 6 (IL6)	NM_000600	NM_000600.3	5'-gatgagtacaaaagtctgatcca- 3'	5'-ctgcagccactggttctgt-3'	130 nt